This move is archived. Current quotes and coverage live on the stock page.
Get EPRX alerts:
Eupraxia Pharmaceuticals Inc saw a significant drop in its stock price today, raising concerns among investors about its market positioning.
Eupraxia Pharmaceuticals Inc (EPRX.TO) experienced a notable decline of 5.73% in its stock price during the last trading session, closing at CA$8.22. This downturn has prompted investors to reassess the company's recent performance and future prospects.
Investor takeaway: With no recent news to explain the decline, investors may need to consider the broader market conditions and the company's financial health as they evaluate their positions.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$732.75M
52W high
$12.86
52W low
$7.15
1W change
+6.95%
Beta
1.49
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 44.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.00
+44.4% Upside
Current Price
C$11.08
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
76.2%
Annualized
90-Day Vol
66.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$13.25
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$11.76 | C$9.04 โ C$15.30 |
| 60 trading days | C$12.48 | C$8.60 โ C$18.11 |
| 90 trading days | C$13.25 | C$8.40 โ C$20.89 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Eupraxia Pharmaceuticals Inc down 5.73% today
The company's market cap stands at CA$552 million, highlighting its small-cap status and the potential for significant price swings.
Bull case
Eupraxia has shown promise in its clinical trials, especially with EP-104GI. If these trials succeed, they could lead to substantial growth for the company.
Bear case
The absence of recent positive news and the stock's volatility might suggest underlying issues that could shake investor confidence in the future.
Advertisement
Market Reaction to Eupraxia's Stock Decline
The 5.73% drop in Eupraxia's stock price has raised eyebrows among investors. With no recent announcements or financial results to explain this decline, many are left speculating about potential factors influencing market sentiment. The company's small-cap status often leads to heightened volatility, making it essential for investors to remain vigilant.
Future Outlook for Eupraxia Pharmaceuticals
Despite today's downturn, Eupraxia Pharmaceuticals has a promising product pipeline, particularly with EP-104GI. Positive results from ongoing clinical trials could reverse negative sentiment and drive stock prices higher. However, investors should keep an eye on market trends and any forthcoming news that may impact the company's trajectory. For more details on its financial health, check out our EPRX.TO stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
